Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Off-label Use of Drugs in Children Reported: Korosho Panel
April 5, 2004
- DIAGNOSTIC NEWS IN BRIEF
March 29, 2004
- Takeda's Income from IP to Exceed \60 Bil. in FY2003
March 29, 2004
- WORLD NEWS IN BRIEF
March 29, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 29, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 29, 2004
- American College of Cardiology 53rd Annual Scientific Session
March 29, 2004
- Outsources of Hospital Services Increasing: JHEF Survey
March 29, 2004
- OTC NEWS IN BRIEF
March 29, 2004
- OBITUARY
March 29, 2004
- Switch to GE Injectables to Save \200 Mil. Annually: St. Marianna Univ. Hospital
March 29, 2004
- Clinical Oncologist Certification System to Be Established
March 29, 2004
- REGULATORY NEWS IN BRIEF
March 29, 2004
- NHI Prices of 35 Unprofitable Products to Be Raised in April
March 29, 2004
- BUSINESS NEWS IN BRIEF
March 29, 2004
- Drug Makers Need Research Tools from Universities: JPMA Symposium
March 29, 2004
- Merck Ltd to Focus on Cancer, Emergency Care
March 29, 2004
- Leading Makers to Obtain Evidence on Their Defensive Factor-enhancing Anti-Ulcer Drugs
March 29, 2004
- 4 Potential Blockbusters in the Pipeline: Eisai
March 29, 2004
- GSK to Strengthen Promotion of Serevent for COPD
March 29, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…